401 related articles for article (PubMed ID: 27570458)
1. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
Pinilla-Ibarz J; Sweet KL; Corrales-Yepez GM; Komrokji RS
Onco Targets Ther; 2016; 9():4937-57. PubMed ID: 27570458
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.
Bisen A; Claxton DF
Adv Exp Med Biol; 2013; 779():179-96. PubMed ID: 23288640
[TBL] [Abstract][Full Text] [Related]
3. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
4. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.
Vainchenker W; Leroy E; Gilles L; Marty C; Plo I; Constantinescu SN
F1000Res; 2018; 7():82. PubMed ID: 29399328
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.
Sonbol MB; Firwana B; Zarzour A; Morad M; Rana V; Tiu RV
Ther Adv Hematol; 2013 Feb; 4(1):15-35. PubMed ID: 23610611
[TBL] [Abstract][Full Text] [Related]
6. Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)?
Sora F; Chiusolo P; Autore F; Giammarco S; Laurenti L; Innocenti I; Metafuni E; Galli E; Bacigalupo A; Sica S
Mediterr J Hematol Infect Dis; 2021; 13(1):e2021062. PubMed ID: 34804436
[TBL] [Abstract][Full Text] [Related]
7. Co-occurrence of
Zanelli M; Bisagni A; Sanguedolce F; Broggi G; Fragliasso V; Zizzo M; Palicelli A; Martino G; Cresta C; Caprera C; Corsi M; Gentile P; Gozzi F; Trombetta D; Parente P; Caltabiano R; Koufopoulos N; Cimino L; Cavazza A; Fraternali Orcioni G; Ascani S
Front Oncol; 2023; 13():1329298. PubMed ID: 38282677
[TBL] [Abstract][Full Text] [Related]
8. Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Lewandowski K; Gniot M; Wojtaszewska M; Kanduła Z; Becht R; Paczkowska E; Mędraś E; Wasilewska E; Iwoła M
Int J Lab Hematol; 2018 Jun; 40(3):366-371. PubMed ID: 29508552
[TBL] [Abstract][Full Text] [Related]
9. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
10. When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms.
Oh ST
Ther Adv Hematol; 2011 Feb; 2(1):11-9. PubMed ID: 23556072
[TBL] [Abstract][Full Text] [Related]
11. Disease modifying agents of myeloproliferative neoplasms: a review.
Lee SE
Blood Res; 2021 Apr; 56(S1):S26-S33. PubMed ID: 33935032
[TBL] [Abstract][Full Text] [Related]
12. Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
Singdong R; Siriboonpiputtana T; Chareonsirisuthigul T; Kongruang A; Limsuwanachot N; Sirirat T; Chuncharunee S; Rerkamnuaychoke B
Asian Pac J Cancer Prev; 2016 Oct; 17(10):4647-4653. PubMed ID: 27892678
[TBL] [Abstract][Full Text] [Related]
13. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.
Masarova L; Bose P; Verstovsek S
Curr Hematol Malig Rep; 2019 Aug; 14(4):310-327. PubMed ID: 31228096
[TBL] [Abstract][Full Text] [Related]
14. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.
Verma T; Papadantonakis N; Peker Barclift D; Zhang L
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339265
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
[TBL] [Abstract][Full Text] [Related]
17. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
Rosenthal A; Mesa RA
Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
[TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.
Reuther GW
Prog Mol Biol Transl Sci; 2016; 144():437-484. PubMed ID: 27865464
[TBL] [Abstract][Full Text] [Related]
19. JAK-mutant myeloproliferative neoplasms.
Levine RL
Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
[TBL] [Abstract][Full Text] [Related]
20. AXL Inhibition Represents a Novel Therapeutic Approach in
Beitzen-Heineke A; Berenbrok N; Waizenegger J; Paesler S; Gensch V; Udonta F; Vargas Delgado ME; Engelmann J; Hoffmann F; Schafhausen P; von Amsberg G; Riecken K; Beumer N; Imbusch CD; Lorens J; Fischer T; Pantel K; Bokemeyer C; Ben-Batalla I; Loges S
Hemasphere; 2021 Sep; 5(9):e630. PubMed ID: 34396051
[No Abstract] [Full Text] [Related]
[Next] [New Search]